Yahoo España Búsqueda web

Search results

1. www.facebook.com › public › Jerry-McMahonJerry McMahon Profiles | Facebook

   www.facebook.com › public › Jerry-McMahon

   • En caché

   View the profiles of people named Jerry McMahon. Join Facebook to connect with Jerry McMahon and others you may know. Facebook gives people the power to...

2. www.bloomberg.com › profile › personJerry McMahon, Storm Therapeutics Ltd: Profile and Biography

   www.bloomberg.com › profile › person

   • En caché

   Jerry McMahon is President/CEO at Storm Therapeutics Ltd. See Jerry McMahon's compensation, career history, education, & memberships.

3. www.stormtherapeutics.com › news › press-releasesSTORM Therapeutics Appoints Dr. Jerry McMahon as Chief Executive...

   www.stormtherapeutics.com › news › press-releases

   • En caché

   7 de sept. de 2022 · Dr. Jerry McMahon added: “STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.

4. tw2marketing.com › seltzer-caplan-mcmahon-vitek-announces-new-leadership-rolesSeltzer Caplan McMahon Vitek Announces New Leadership Roles

   tw2marketing.com › seltzer-caplan-mcmahon-vitek-announces-new-leadership-roles

   • En caché

   The new leadership roles are related to the retirement of Gerald McMahon, who leaves the firm after 54 years. SCMV is the only firm with which McMahon has practiced. “Our firm is celebrating its 70 th anniversary, and Jerry has been a significant part of our success,” states Caplan.

5. www.m-ventures.com › de › newsSTORM Therapeutics Appoints New CEO - M Ventures

   www.m-ventures.com › de › news

   • En caché

   7 de sept. de 2022 · Dr. Jerry McMahon added: “STORM is well positioned to fulfil its ambition of becoming the global leader in the field of RME. STORM’s first-in-class clinical candidate STC-15, an orally-bioavailable, highly selective METTL3 inhibitor, is on schedule to start initial clinical studies in solid tumors in 2022 and will be the first first-ever RME inhibitor molecule to enter clinical development.

6. www.facebook.com › jerryJerry McMahon - Facebook

   www.facebook.com › jerry

   Jerry McMahon is on Facebook. Join Facebook to connect with Jerry McMahon and others you may know. Facebook gives people the power to share and makes the world more open and connected.